BioBusiness

Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup: Millennium CEO Deborah Dunsire is retirin... bit.ly/1953hjo

Dunsire Out At Millennium/Takeda, Replaced by Anna Protopapas: Luke Timmerman Deborah Dunsire, the CEO w... bit.ly/13GA4uo

Rockwell Medical Set to Disrupt Dialysis With New Drugs, DaVita Deal: Sarah Schmid In the late 1990s, Wi... bit.ly/10wbihV

Dendreon Shares Fall Again, as Provenge Sales Slump: Luke Timmerman Dendreon has made a habit of disappo... bit.ly/193VfXX

U.S. drug market shrinks for first time: U.S. drug spending dropped last year. While that may be welcome news ... bit.ly/10vpnfx

The Next Billionaire: A Statistician Who Changed Medicine: Staying up-to-date has never been simpler. Sign up... bit.ly/193CMur

San Diego Life Sciences Roundup: Receptos, Arena, NuVasive, & More: Bruce V. Bigelow Amid the hectic pac... bit.ly/15Oaw2H

Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up: Bernadette Tansey At one edge of the s... bit.ly/1306Ljz

Biotech Receptos claims $73M IPO prize to fuel oral MS contender: San Diego-based biotech Receptos has priced ... bit.ly/13ERlUQ

Global CRO Quintiles rakes in $947M as its hot IPO sells at top range: The global CRO Quintiles won some enthu... bit.ly/13E7RnY

Trevena lands $430M Forest deal, $60M venture round as heart drug heads to PhIIb: bit.ly/13DVsRa

Inviragen, Global Health Vaccine Maker, Bought by Takeda for $35M: Michael Davidson Japanese pharmaceuti... bit.ly/13A3Cdh

Nimbus Discovery, Shire to Co-Develop Oral Rare Disease Drugs: Ben Fidler Nimbus Discovery splashed onto... bit.ly/16ZgnC6

Big Pharma CEOs Rake in $1.57 Billion in Pay: Staying up-to-date has never been simpler. Sign up for the free... bit.ly/13ziNDy

Fast-growing Biogen Idec bursts the seams at new Cambridge HQ: When George Scangos took the helm at Biogen Ide... bit.ly/18Ypr6H

The pharma spin-offs have just begun: After all, investors and shareholders responded strongly to Pfizer's ani... bit.ly/13yQjd6

Genomics, Biotechnology's Oldest Next Big Thing: The economist Edward Fiedler famously said "He who lives by t... bit.ly/15GpgAy

Startup biotech charges into PhII with $23M bankroll for rare disease drugs: A little more than a year ago the... bit.ly/18XzqJE

Lumena Raises $23 Million to Advance Drug for Rare Liver Diseases: Bruce V. Bigelow San Diego-based Lume... bit.ly/15FjIGx

Will $28M in Debt Financing Push Good Start Genetics to Big Finish?: Ben Fidler Six years ago, Good Star... bit.ly/13xoge1